Resectable Biliary Tract Cancer
2 clinical trials · Condition
◉ Watch Resectable Biliary Tract Cancer
| Record | Firm | Date |
|---|---|---|
| Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer (NCT05640791) | Tianjin Medical University Cancer Institute and Hospital | 2023-01-12 |
| Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer (NCT03768531) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-06-14 |
Track Resectable Biliary Tract Cancer automatically
Every clearance here is in the API, with alerts when new ones post.